The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.

Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG cohorts, indicating clinician-driven personalization rather than cardiovascular ...

Tanya Siddiqi, MD, discusses long-term outcomes with first-line zanubrutinib (Brukinsa) in patients with high-risk chronic ...

Tanya Siddiqi, MD, shares her personal experience using continuous BTK inhibitor therapy for the treatment of patients with ...

Pemivibart blocks spike RBD interaction with ACE2 and received FDA EUA (Pemgarda) for pre-exposure prophylaxis in moderately to severely immunocompromised patients, not for treatment or postexposure ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

INDIANAPOLIS, April 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent ...